Yahoo Finance

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs

SAN FRANCISCO, CA / ACCESSWIRE / November 6, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that the U.S. Food and Drug ...
Yahoo Finance

Felycin®-CA1 (Sirolimus Delayed-Release Tablets) is the First and Only Drug FDA Approved for the Management of Ventricular Hypertrophy in Cats with Subclinical Hypertrophic ...

Felycin®-CA1 is now available by prescription via licensed veterinarians, and PBI-Gordon Companies, Inc. confirms that it has no affiliation with any online companies offering rapamycin (sirolimus) ...
USA Today

Company Advances Towards Full FDA Approval of Crofelemer for Chemotherapy-Induced Diarrhea

SAN FRANCISCO, CA / ACCESS Newswire / April 29, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced topline results from the completion of its effectiveness trial of crofelemer (FDA ...
USA Today

Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

Company strategy: In discussions with multiple potential animal health company partners to collaborate to bring Canalevia ®, conditionally approved for CID, to regulatory approval and ...
Nasdaq

FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs

Canalevia®-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA Crofelemer, Jaguar's novel, oral plant-based drug ...